C4 Therapeutics, Inc. — Director's Dealing 2021

Oct 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-10-01

Reporting Person: Crystal Adam (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-01	Common Stock	M	15000	$4.98	Acquired	15000	Direct
2021-10-01	Common Stock	S	1712	$44.2502	Disposed	13288	Direct
2021-10-01	Common Stock	S	8176	$45.3233	Disposed	5112	Direct
2021-10-01	Common Stock	S	5112	$45.9935	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-01	Stock Option (Right to Buy)	$4.98	M	15000	Disposed	2030-07-02	Common Stock (15000)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.57 to $44.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.85 to $45.845. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.89 to $46.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020.